Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential

Bibliography

• Kim S, Ng WK, Dong Y, et al. Preparation and physicochemical characterization of trans-resveratrol nanoparticles by temperature-controlled antisolvent precipitation. J Food Eng 2012;108:37-42
   Web of Science ®Google Scholar
• Singh G, Pai RS, Pandit V. Development and validation of a HPLC method for the determination of trans-resveratrol in spiked human plasma. J Adv Pharm Technol Res 2012;3:130-5
   PubMedGoogle Scholar
• Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations. J Control Release 2012;158:182-93
   PubMed Web of Science ®Google Scholar
• Ortuno J, Covas MI, Farre M, et al. Matrix effects on the bioavailability of resveratrol in humans. Food Chem 2010;120:1123-30
   Web of Science ®Google Scholar
• Kristl J, Teskac K, Caddeo C, et al. Improvement of cellular stress response on resveratrol in liposomes. Eur J Pharm Biopharm 2009;73:253-9
   PubMed Web of Science ®Google Scholar
• Singh G, Pai RS, Pandit V. In vivo pharmacokinetic applicability of a simple and validated HPLC method for orally administered trans-resveratrol loaded polymeric nanoparticles to rats. J Pharm Investig 2013. [Epub ahead of print]
   Google Scholar
• Das S, Ng KY. Quantification of trans-resveratrol in rat plasma by a simple and sensitive high performance liquid chromatography method and its application in pre-clinical study. J Liq Chromatogr Relat Technol 2011;34:1399-414
   Web of Science ®Google Scholar
• Amiot MJ, Romier B, Dao TM, et al. Optimization of trans-resveratrol bioavailability for human therapy. Biochimie 2013;95:1233-8
   PubMed Web of Science ®Google Scholar
• Gambini J, Lopez-Grueso R, Olaso-González G, et al. Resveratrol: distribution, properties and perspectives. Rev Esp Geriatr Gerontol 2013;48:79-88
   PubMedGoogle Scholar
• Sale S, Verschoyle RD, Boocock D, et al. Pharmacokinetics inmice and growth- inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans-3,4,5,4′-tetramethoxystilbene. Br J Cancer 2004;90:736-44
   PubMed Web of Science ®Google Scholar
• Yeo SC, Ho PC, Lin HS. Pharmacokinetics of pterostilbene in sprague-dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol Nutr Food Res 2013;57:1015-25
   PubMed Web of Science ®Google Scholar
• Hung CF, Chen JK, Liao MH, et al. Development and evaluation of emulsion-liposome blends for resveratrol delivery. J Nanosci Nanotechnol 2006;6:2950-8
   PubMed Web of Science ®Google Scholar
• Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-impact of different polymers. J Pharm Sci 2013;102:171-84
   PubMed Web of Science ®Google Scholar
• Troche-Pesqueira E, Perez-Juste I, Navarro-Vazquez A, Magdalena Cid M. A beta-cyclodextrin–resveratrol inclusion complex and the role of geometrical and electronic effects on its electronic induced circular dichroism. RSC Adv 2013;3:10242-50
   Web of Science ®Google Scholar
• Nam JB, Ryu JH, Kim JW, et al. Stabilization of resveratrol immobilized in monodisperse cyano-functionalized porous polymeric microspheres. Polymer (Guildf) 2005;46:8956-63
   Web of Science ®Google Scholar
• Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008;4:273-82
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504
   PubMed Web of Science ®Google Scholar
• Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991;7:71-86
   Web of Science ®Google Scholar
• Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989;41:809-12
   PubMed Web of Science ®Google Scholar
• Damge C, Michel C, Aprahamian M, et al. Nanocapsules as carriers for oral peptide delivery. J Control Release 1990;13:233-9
   Web of Science ®Google Scholar
• Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 1996;189:503-5
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Islambulchilar Z. The utility of rat jejunal permeability for biopharmaceutics classification system. Drug Dev Ind Pharm 2009;35:1496-502
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu Y, Lin H, Hu M. In situ single-pass perfused rat intestinal model for absorption and metabolism. In: Yan Z, Caldwell GW, editors, Optimization in drug discovery, methods in pharmacology and toxicology. Springer protocols, New Jersey; 2004. p. 65-76
   Google Scholar
• Singh G, Pai RS, Devi VK. Response surface methodology and process optimization of sustained release pellets using taguchi orthogonal array design and central composite design. J Adv Pharm Technol Res 2012;3:30-40
   PubMedGoogle Scholar
• Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv 2011;8:1341-60
   PubMed Web of Science ®Google Scholar
• Singh G, Pai RS. Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine. Drug Deliv 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Quevedo MA, Nieto LE, Brinon MC. P-glycoprotein limits the absorption of the anti-HIV drug zidovudine through rat intestinal segments. Eur J Pharm Sci 2011;43:151-9
   PubMed Web of Science ®Google Scholar
• Lv S, Tang Z, Song W, et al. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater 2013;9:9330-42
   PubMed Web of Science ®Google Scholar
• Lu Y, Kim S, Park K. In vitro/in vivo correlation: perspectives on model development. Int J Pharm 2011;418:142-8
   PubMed Web of Science ®Google Scholar
• Q1A(R2), Stability Testing of New Drug Substances and Products, 2003
   Google Scholar
• USP, USP 34, NF 29. The United States pharmacopeia and the National formulary. The United States Pharmacopeial Convention, Rockwille, MD; 2011. p. 20852
   Google Scholar
• Ho YF, Lai MY, Yu HY, et al. Application of rat in situ single-pass intestinal perfusion in the evaluation of pre systemic extraction of indinavir under different perfusion rates. J Formos Med Assoc 2008;107:37-45
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang H, Yu M, et al. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2012;81:248-56
   PubMed Web of Science ®Google Scholar
• Feng S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (taxol) from nanospheres of biodegradable polymers. J Control Release 2001;71:53-69
   PubMed Web of Science ®Google Scholar
• Doornbos CA, Haan PD. Optimization techniques in formulation and processing. In: Swarbrick J, Boylan JC, editors, Encyclopedia of pharmaceutical technology. Marcel Dekker, New York; 1995. p. 77-160
   Google Scholar
• Fonseca C, Simões S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002;83:273-86
   PubMed Web of Science ®Google Scholar
• Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Rel 2007;119:77-85
   PubMed Web of Science ®Google Scholar
• Marier JF, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002;302:369-73
   PubMed Web of Science ®Google Scholar
• Singh G, Pai RS. Trans-resveratrol self nano-emulsifying drug delivery systems (SNEDDS) with enhanced bioavailability potential: Optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies. Drug Deliv 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lee J, Lee IH, et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008;51:6442-9
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu A, Sun M, et al. Enhancement of oral bioavailability of puerarin by polybutylcyanoacrylate nanoparticles. J Nanomater 2011;2011:8, [Article ID 126562], doi:10.1155/2011/126562
   Google Scholar
• Zhanga J, Lva H, Jiang K, Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm 2011;420:180-8
   PubMedGoogle Scholar
• Jiao Y, Ubrich N, Arvier MM, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002;105:230-5
   PubMed Web of Science ®Google Scholar
• Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557-70
   PubMed Web of Science ®Google Scholar